Literature DB >> 23290560

Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder.

Joseph O'Neill1, Eda Gorbis, Jamie D Feusner, Jenny C Yip, Susanna Chang, Karron M Maidment, Jennifer G Levitt, Noriko Salamon, John M Ringman, Sanjaya Saxena.   

Abstract

The neurophysiological bases of cognitive-behavioral therapy (CBT) for obsessive-compulsive disorder (OCD) are incompletely understood. Previous studies, though sparse, implicate metabolic changes in pregenual anterior cingulate cortex (pACC) and anterior middle cingulate cortex (aMCC) as neural correlates of response to CBT. The goal of this pilot study was to determine the relationship between levels of the neurochemically interlinked metabolites glutamate + glutamine (Glx) and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (tNAA) in pACC and aMCC to pretreatment OCD diagnostic status and OCD response to CBT. Proton magnetic resonance spectroscopic imaging ((1)H MRSI) was acquired from pACC and aMCC in 10 OCD patients at baseline, 8 of whom had a repeat scan after 4 weeks of intensive CBT. pACC was also scanned (baseline only) in 8 age-matched healthy controls. OCD symptoms improved markedly in 8/8 patients after CBT. In right pACC, tNAA was significantly lower in OCD patients than controls at baseline and then increased significantly after CBT. Baseline tNAA also correlated with post-CBT change in OCD symptom severity. In left aMCC, Glx decreased significantly after intensive CBT. These findings add to evidence implicating the pACC and aMCC as loci of the metabolic effects of CBT in OCD, particularly effects on glutamatergic and N-acetyl compounds. Moreover, these metabolic responses occurred after just 4 weeks of intensive CBT, compared to 3 months for standard weekly CBT. Baseline levels of tNAA in the pACC may be associated with response to CBT for OCD. Lateralization of metabolite effects of CBT, previously observed in subcortical nuclei and white matter, may also occur in cingulate cortex. Tentative mechanisms for these effects are discussed. Comorbid depressive symptoms in OCD patients may have contributed to metabolite effects, although baseline and post-CBT change in depression ratings varied with choline-compounds and myo-inositol rather than Glx or tNAA.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23290560      PMCID: PMC3672238          DOI: 10.1016/j.jpsychires.2012.11.010

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  71 in total

1.  Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder.

Authors:  Murat Yücel; Ben J Harrison; Stephen J Wood; Alex Fornito; Robert M Wellard; Jesus Pujol; Kerrie Clarke; Mary L Phillips; Michael Kyrios; Dennis Velakoulis; Christos Pantelis
Journal:  Arch Gen Psychiatry       Date:  2007-08

2.  Relevance of orbitofrontal neurochemistry for the outcome of cognitive-behavioural therapy in patients with obsessive-compulsive disorder.

Authors:  Bartosz Zurowski; Andreas Kordon; Wolfgang Weber-Fahr; Ulrich Voderholzer; Anne Katrin Kuelz; Tobias Freyer; Karina Wahl; Christian Büchel; Fritz Hohagen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

3.  Method to correlate 1H MRSI and 18FDG-PET.

Authors:  J O'Neill; J L Eberling; N Schuff; W Jagust; B Reed; G Soto; F Ezekiel; G Klein; M W Weiner
Journal:  Magn Reson Med       Date:  2000-02       Impact factor: 4.668

Review 4.  Glutamate uptake.

Authors:  N C Danbolt
Journal:  Prog Neurobiol       Date:  2001-09       Impact factor: 11.685

Review 5.  Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling.

Authors:  M H Baslow
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

6.  Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder.

Authors:  Jun Soo Kwon; Jae-Jin Kim; Dong Woo Lee; Jae Sung Lee; Dong Soo Lee; Myung-Sun Kim; In Kyoon Lyoo; Maeng Je Cho; Myung Chul Lee
Journal:  Psychiatry Res       Date:  2003-01-20       Impact factor: 3.222

7.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

8.  Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro.

Authors:  Carl D Holmgren; Marat Mukhtarov; Anton E Malkov; Irina Y Popova; Piotr Bregestovski; Yuri Zilberter
Journal:  J Neurochem       Date:  2009-11-24       Impact factor: 5.372

9.  Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder.

Authors:  Eriko Nakatani; Akiko Nakgawa; Yoko Ohara; Shoko Goto; Naruhiko Uozumi; Michiyo Iwakiri; Yukari Yamamoto; Keisuke Motomura; Yasuro Iikura; Toshiko Yamagami
Journal:  Psychiatry Res       Date:  2003-10-30       Impact factor: 3.222

10.  Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study.

Authors:  Ethan A Smith; Aileen Russell; Elisa Lorch; S Preeya Banerjee; Michelle Rose; Jennifer Ivey; Rashmi Bhandari; Gregory J Moore; David R Rosenberg
Journal:  Biol Psychiatry       Date:  2003-12-15       Impact factor: 13.382

View more
  19 in total

1.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

2.  Differential neuroimaging indices in prefrontal white matter in prenatal alcohol-associated ADHD versus idiopathic ADHD.

Authors:  Joseph O'Neill; Mary J O'Connor; Victor Yee; Ronald Ly; Katherine Narr; Jeffrey R Alger; Jennifer G Levitt
Journal:  Birth Defects Res       Date:  2019-01-29       Impact factor: 2.344

3.  Caudate volume differences among treatment responders, non-responders and controls in children with obsessive-compulsive disorder.

Authors:  Edoardo F Q Vattimo; Vivian B Barros; Guaraci Requena; João R Sato; Daniel Fatori; Euripedes C Miguel; Roseli G Shavitt; Marcelo Q Hoexter; Marcelo C Batistuzzo
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-04-10       Impact factor: 4.785

4.  Investigating neural mechanisms of change of cognitive behavioural therapy for chronic fatigue syndrome: a randomized controlled trial.

Authors:  Marieke E van Der Schaaf; Iris C Schmits; Megan Roerink; Dirk E M Geurts; Ivan Toni; Karin Roelofs; Floris P De Lange; Urs M Nater; Jos W M van der Meer; Hans Knoop
Journal:  BMC Psychiatry       Date:  2015-07-03       Impact factor: 3.630

5.  Magnetic Resonance Spectroscopy (MRS) and Positron Emission Tomography (PET) Imaging in Obsessive-Compulsive Disorder.

Authors:  Marjan Biria; Lucia-Manuela Cantonas; Paula Banca
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 6.  Neuroimaging for psychotherapy research: current trends.

Authors:  Carol P Weingarten; Timothy J Strauman
Journal:  Psychother Res       Date:  2014-02-17

Review 7.  Can Neuroimaging Provide Reliable Biomarkers for Obsessive-Compulsive Disorder? A Narrative Review.

Authors:  Ilana Frydman; Juliana B de Salles Andrade; Paula Vigne; Leonardo F Fontenelle
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

8.  Cingulate and thalamic metabolites in obsessive-compulsive disorder.

Authors:  Joseph O'Neill; Tsz M Lai; Courtney Sheen; Giulia C Salgari; Ronald Ly; Casey Armstrong; Susanna Chang; Jennifer G Levitt; Noriko Salamon; Jeffry R Alger; Jamie D Feusner
Journal:  Psychiatry Res Neuroimaging       Date:  2016-05-24       Impact factor: 2.376

9.  A new conception and subsequent taxonomy of clinical psychological problems.

Authors:  Gary M Bakker
Journal:  BMC Psychol       Date:  2019-07-10

Review 10.  New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity.

Authors:  Naomi A Fineberg; Samuel R Chamberlain; Anna E Goudriaan; Dan J Stein; Louk J M J Vanderschuren; Claire M Gillan; Sameer Shekar; Philip A P M Gorwood; Valerie Voon; Sharon Morein-Zamir; Damiaan Denys; Barbara J Sahakian; F Gerard Moeller; Trevor W Robbins; Marc N Potenza
Journal:  CNS Spectr       Date:  2014-02       Impact factor: 3.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.